MetaCap

Avalyn Pharma Balance Sheet

NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

25.76+0.04 (+0.16%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Avalyn Pharma has no annual balance sheet on file yet, so quarterly figures are shown instead.

Avalyn Pharma financial position

As of Jun 30, 2026, Avalyn Pharma reported total assets of $425.4 million against total liabilities of $27.1 million. Shareholders' equity stood at $398.3 million, or 93.6% of assets. The company held $264.2 million in cash and equivalents against $14.8 million of debt, a net cash position of $249.4 million.

The current ratio (current assets divided by current liabilities) was 33.12, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.04.

Summary generated from market data by MetaCap's automated system. Methodology

Avalyn Pharma balance sheet (quarterly)

Avalyn Pharma quarterly balance sheet
Quarter (USD)Q2 20262026-06-30Q1 20262026-03-31Q? 20252025-06-30Q? 20252025-03-31
Cash & Equivalents264.20M92.31M61.30M28.80M
Short-Term Investments88.23M30.82M——
Total Current Assets357.99M129.99M——
Property, Plant & Equipment1.21M1.26M——
Long-Term Investments61.10M———
Total Assets425.45M135.66M——
Accounts Payable2.65M3.15M——
Total Current Liabilities10.81M11.79M——
Long-Term Debt14.80M14.81M——
Total Liabilities27.10M27.69M——
Shareholders' Equity398.35M-264.25M-194.39M-191.57M
Retained Earnings-321.17M-292.23M——
Total Debt14.80M14.81M——
Net Cash (Debt)337.62M108.32M61.30M28.80M
Shares Outstanding44.33M1.23M——

This table shows 4 quarterly periods of Avalyn Pharma's balance sheet, from Q2 2026 back to Q? 2025, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow AVLN's reporting calendar. What is a balance sheet?

More financial data